{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:41:37Z","timestamp":1794004897444,"version":"4.8.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cpcardiol.2025.103149","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:10:03Z","timestamp":1754435403000},"page":"103149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["SGLT2 inhibitors and cardiac fibrosis: A comprehensive review"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis K","family":"Vlachakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Apostolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikias","family":"Milaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ktenopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Grigoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Klisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Karagiannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Fyntanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios P","family":"Antoniadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2025.103149_bib0001","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41569-025-01134-1","article-title":"Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition","volume":"22","author":"Figueroa-Ju\u00e1rez","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.529075","article-title":"The dynamic interplay between cardiac inflammation and fibrosis","volume":"11","author":"Thomas","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac fibrosis: the fibroblast awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.010","article-title":"A holistic view of SGLT2 inhibitors: from cardio-renal management to cognitive and andrological aspects","author":"Cannarella","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","article-title":"Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review","volume":"24","author":"Yoo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0008","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk","volume":"15","author":"Jasleen","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0009","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0010","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0011","article-title":"Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: a meta-analysis of clinical studies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0012","first-page":"1","article-title":"The SGLT2 inhibitor canagliflozin attenuates mitochondrial oxidative stress and alterations of calcium handling induced by high glucose in human cardiac fibroblasts","author":"Varzideh","year":"2025","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1499542","article-title":"Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Yuan","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103149_bib0014","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1007\/s11010-025-05294-z","article-title":"SGLT2i continuously prevents cardiac hypertrophy by reducing ferroptosis via AMPK up-regulation","volume":"480","author":"Zhao","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-021-01322-6","article-title":"The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats","volume":"20","author":"Daud","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0016","first-page":"1","article-title":"SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach","volume":"3","author":"McLean","year":"2025","journal-title":"Npj Metab Heal Dis"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103149_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082824","article-title":"Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease","volume":"12","author":"Rastogi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0019","article-title":"SGLT2 inhibitors and Mortality in Diabetic Cancer Patients. Cardioprotective and Anticancer effects","volume":"6","author":"Keramida","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother. Published online"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2020.11.029","article-title":"The pleiotropic effects of SGLT2 inhibitors: remodeling the treatment of heart failure","volume":"77","author":"Goldberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0022","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.2174\/0113816128304097240529053538","article-title":"Therapeutic potential of sodium-glucose Co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with acute coronary syndrome: a review of clinical evidence","volume":"30","author":"Karakasis","year":"2024","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80829-w","article-title":"Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122354","article-title":"Empagliflozin protects against isoprenaline-induced fibrosis in rat heart through modulation of TGF-\u03b2\/SMAD pathway","volume":"337","author":"Elsayed","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12933-023-01756-0","article-title":"Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis","volume":"22","author":"Chung","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct cardiac actions of the sodium glucose Co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0027","article-title":"Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-\u03b21\/smad signaling pathway in a normoglycemic Rabbit model of chronic heart failure","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103149_bib0028","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/ph18030313","article-title":"Cardiac fibrosis:Mechanistic discoveries linked to SGLT2 inhibitors","volume":"18","author":"Rolski","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0029","first-page":"10950","article-title":"The cardioprotective effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in rats with isoproterenol-induced cardiomyopathy","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120862","article-title":"Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress","volume":"307","author":"Bugga","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0032","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0033","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/clinchem\/hvaa277","article-title":"Sodium-glucose Co-transporter 2 inhibitors and insights from biomarker measurement in heart failure patients","volume":"67","author":"Ibrahim","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103149_bib0036","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines12040765","article-title":"Diabetic cardiomyopathy-from basics through diagnosis to treatment","volume":"12","author":"Radzioch","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0037","article-title":"Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies","volume":"23","author":"Rizza","year":"2024","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41420-023-01553-4","article-title":"Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions","volume":"9","author":"Huo","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0039","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00018-025-05793-8","article-title":"Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin","volume":"82","author":"Gao","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0041","article-title":"A Human engineered heart tissue-derived lipotoxic diabetic cardiomyopathy model revealed early benefits of Empagliflozin","author":"Cai","year":"2025","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Ger"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123721","article-title":"Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin","volume":"375","author":"Mayyas","year":"2025","journal-title":"Life Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0044","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12012-024-09945-3","article-title":"Dapagliflozin suppresses high glucose-induced proliferation, oxidative stress, and fibrosis by reducing Mettl3-induced m6A modification in marcks mRNA","volume":"25","author":"Shi","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12916-022-02485-z","article-title":"Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling","volume":"20","author":"Lee","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0046","doi-asserted-by":"crossref","first-page":"608","DOI":"10.17305\/bb.2024.11361","article-title":"Dapagliflozin and Sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model","volume":"25","author":"Lee","year":"2025","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.908037","article-title":"Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway","volume":"9","author":"Zhan","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103149_bib0048","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/ijms26010209","article-title":"Atrial fibrosis in Atrial fibrillation: mechanistic insights, diagnostic challenges, and emerging therapeutic targets","volume":"26","author":"Karakasis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.103010","article-title":"Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress","volume":"69","author":"Cai","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0051","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12872-021-02024-3","article-title":"Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study","volume":"21","author":"Oka","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0052","article-title":"Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice","volume":"12","author":"Liu","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0053","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12933-023-02040-x","article-title":"SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1","volume":"22","author":"Wang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0054","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41401-024-01265-0","article-title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway","volume":"45","author":"Ni","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175194","article-title":"Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure","volume":"931","author":"Shiraki","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0056","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000533277","article-title":"Canagliflozin ameliorates ventricular remodeling through apelin\/Angiotensin-converting enzyme 2 signaling in heart failure with preserved ejection fraction rats","volume":"108","author":"Zhang","year":"2023","journal-title":"Pharmacology"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/14791641231197106","article-title":"Dapagliflozin attenuates cardiac remodeling and dysfunction in rats with \u03b2-adrenergic receptor overactivation through restoring calcium handling and suppressing cardiomyocyte apoptosis","volume":"20","author":"Liu","year":"2023","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0058","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00210-023-02655-7","article-title":"Empagliflozin improves cardiac function in rats with chronic heart failure","volume":"397","author":"Wang","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0059","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13098-023-01116-8","article-title":"Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes","volume":"15","author":"Feng","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175531","article-title":"Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics","volume":"942","author":"Lyu","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0061","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019274","article-title":"Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction","volume":"10","author":"Lin","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0062","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","article-title":"Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study","volume":"30","author":"Albulushi","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0063","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-024-02415-8","article-title":"Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis","volume":"23","author":"Albulushi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0064","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0066","article-title":"Effect of Dapagliflozin on indicators of myocardial fibrosis and levels of inflammatory factors in heart failure patients","volume":"2022","author":"Wang","year":"2022","journal-title":"Dis Markers"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070766","article-title":"Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial","volume":"13","author":"Chai","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0068","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10557-023-07469-6","article-title":"Rationale and design of the SOTA-P-CARDIA trial (ATRU-V): sotagliflozin in HFpEF patients without diabetes","volume":"39","author":"P\u00e9rez","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069641","article-title":"Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial","volume":"13","author":"Raven","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123798","article-title":"Dapagliflozin promotes metabolic reprogramming against myocardial infarction through the MAPK-FOXO3-STC1 and HIF-1a-STC1 pathways","volume":"377","author":"Zhang","year":"2025","journal-title":"Life Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0071","doi-asserted-by":"crossref","DOI":"10.1007\/s11596-025-00076-6","article-title":"Dapagliflozin suppressed cuproptosis and myocardial fibrosis in myocardial infarction through HIF-1\u03b1\/TGF-\u03b2 pathway","author":"Zhang","year":"2025","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0072","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2459\/JCM.0000000000001630","article-title":"Empagliflozin ameliorates ventricular arrhythmias by inhibiting sympathetic remodeling via nerve growth factor\/tyrosine kinase receptor A pathway inhibition","volume":"25","author":"Jing","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116994","article-title":"SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis","volume":"177","author":"Wang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101334","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.995216","article-title":"Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db\/db mice","volume":"9","author":"Tu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0076","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.hrtlng.2025.05.010","article-title":"Effect of SGLT2 inhibitors on inflammatory markers and oxygen consumption in non-diabetic patients with STEMI undergoing primary PCI: a parallel design single blind controlled trial","volume":"73","author":"Li","year":"2025","journal-title":"Heart Lung"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0077","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s12265-021-10192-y","article-title":"Dapagliflozin improves cardiac function, remodeling, myocardial apoptosis, and inflammatory cytokines in mice with myocardial infarction","volume":"15","author":"Wang","year":"2022","journal-title":"J Cardiovasc Transl Res"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103149_bib0078","first-page":"220","article-title":"Effect of DAPAgliflozin on myocardial fibrosis and ventricular function in patients with ST-segment elevation myocardial infarction-DAPA-STEMI trial","volume":"12","author":"Ortega-Paz","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0079","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FJC.0000000000001518","article-title":"Dapagliflozin suppresses isoprenaline-induced cardiac hypertrophy through inhibition of mitochondrial fission","volume":"83","author":"Yang","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0080","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/dom.14814","article-title":"The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis","volume":"24","author":"Moellmann","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0081","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf324","article-title":"Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model","author":"Baka","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0082","first-page":"9","article-title":"Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia\/cardiomyopathy patient","volume":"21","author":"Wang","year":"2019","journal-title":"Eur Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0083","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tcm.2024.09.002","article-title":"Contemporary diagnostic approach to arrhythmogenic cardiomyopathy: the three-step work-up","volume":"35","author":"Graziano","year":"2025","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103149_bib0084","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/jcm13020456","article-title":"Arrhythmogenic cardiomyopathy: definition, classification and arrhythmic risk stratification","volume":"13","author":"Varrenti","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131447","article-title":"Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: european Task Force consensus report","volume":"395","author":"Corrado","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0086","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.3390\/ijms26135954","article-title":"Inflammasome signaling in cardiac arrhythmias: linking inflammation, fibrosis, and electrical remodeling","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0087","article-title":"SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy","volume":"36","author":"Yang","year":"2022","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0088","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: the BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0089","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10787-021-00894-9","article-title":"Cardiac inflammation and fibrosis following chemo\/radiation therapy: mechanisms and therapeutic agents","volume":"30","author":"Yang","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103149_bib0090","article-title":"Cancer therapy-related cardiac dysfunction: a review of current trends in epidemiology","volume":"12","author":"Theofilis","year":"2024","journal-title":"Diagnosis, and Treatment. Biomedicines"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0091","article-title":"Cardiac fibrosis in oncologic therapies","volume":"29","author":"Packard","year":"2022","journal-title":"Curr Opin Physiol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117183","article-title":"Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis","volume":"495","author":"Luo","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0093","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","article-title":"Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3","volume":"96","author":"Chang","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0094","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0096","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","article-title":"Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"95","author":"Chang","year":"2021","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103149_bib0097","first-page":"46","article-title":"Diagnosis and Management of Hypertensive Heart Disease: incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline updates","volume":"12","author":"Wang","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0098","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31083\/j.rcm2503093","article-title":"Hypertensive Heart disease: mechanisms, diagnosis and treatment","volume":"25","author":"Huang","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0099","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/eurheartj\/ehac393","article-title":"Phenotyping the hypertensive heart","volume":"43","author":"Tadic","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/HYPERTENSIONAHA.122.19373","article-title":"Growing heart failure burden of hypertensive heart disease: a call to action","volume":"80","author":"D\u00edez","year":"2023","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103149_bib0101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310710","article-title":"Cardioprotective effects of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension are mediated by the local reduction of sympathetic activity and inflammation","volume":"24","author":"Castoldi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115125","article-title":"Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1\/HIF-1\u03b1 signaling pathway","volume":"165","author":"Yang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149434","article-title":"Integrated analysis reveals ceRNA network of cardiac remodeling by SGLT2 inhibitor in middle-aged hypertensive rats","volume":"696","author":"Xiong","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109024","article-title":"SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis","volume":"110","author":"Long","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2024.02.006","article-title":"Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation","volume":"167","author":"Sheng","year":"2024","journal-title":"Mol Immunol"},{"issue":"25","key":"10.1016\/j.cpcardiol.2025.103149_bib0106","article-title":"Peripartum dapagliflozin improves late-life maternal cardiovascular outcomes in a murine model of superimposed preeclampsia","volume":"4","author":"Hesson","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0107","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74934-z","article-title":"Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease","volume":"14","author":"Souli\u00e9","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0108","first-page":"256","article-title":"Digital twin models in atrial fibrillation: charting the future of precision therapy?","volume":"15","author":"Karakasis","year":"2025","journal-title":"J Pers Med 2025"},{"key":"10.1016\/j.cpcardiol.2025.103149_bib0109","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/jcm14082627","article-title":"Artificial intelligence in atrial fibrillation: from early detection to precision therapy","volume":"14","author":"Karakasis","year":"2025","journal-title":"J Clin Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T17:05:18Z","timestamp":1756832718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":109,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0146280625001690"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103149","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors and cardiac fibrosis: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103149"}}